We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Combined Biosensor Strategy Detects Infectious Pathogens

By LabMedica International staff writers
Posted on 14 Jun 2013
A method has been developed that combines deoxyribozyme technology with gold nanoparticles to give a simple point-of-care (POC) diagnostic technique that can be used in remote settings.

The technique merges the colorimetric coupling of surface plasmons of gold nanoparticles (GNPs) with deoxyribozyme (DNAzyme) signal amplification technology to create a fast and simple detection method for genetic targets with a simple colorimetric readout.

Chemical engineers at the University of Toronto (ON, Canada) implemented a genetic sensing assay in a simple two-step system. More...
In the amplification step, a buffered mix of multicomponent nucleic acid enzymes (MNAzymes) and linkers is added to the sample solution and incubated at 50 °C for one hour. If target sequences are present, they bind and activate the MNAzymes. Each active MNAzyme in turn catalyzes cleavage of multiple linkers, which effectively translates into signal amplification.

Any linkers that remained uncleaved caused aggregation of the corresponding GNP pairs, turning the solution purple. In contrast, linkers cleaved by target-activated MNAzymes were not able to cross-link the associated GNP pairs, and solution remained red. In one test for the pathogen Neisseria gonorrhoeae, the mixtures in the specific detection tubes remained red. Following this method, the scientist successfully detected five targets simultaneously. In addition, the assay with lyophilized components was used to correctly identify gonorrhea, malaria, and hepatitis B virus sequences in a sample mixture that contained three out of the five targets. All RNA-containing Linker DNA strands were obtained from Integrated DNA Technologies (Coralville, IA, USA) in purified lyophilized form and all other DNA sequences were from BioBasic (Markham, ON, Canada).

The authors concluded that the assay can detect multiple genetic sequences in parallel and that it could be easily applied to other nucleic acid targets. The color-based readout does not require any complex equipment and uses stable and cost-effective reagents, making this approach particularly suitable for POC testing. Warren C. W. Chan, PhD, a professor in nanobiotechnology and the senior author, said, “There's been a lot of emphasis in developing simple diagnostics. The question is how do you make it simple enough, portable enough? Gold is the best medium, because it's easy to see. It emits a very intense color." The article was published on March 11, 2013, in the journal Angewandte Chemie.

Related Links:

University of Toronto

Integrated DNA Technologies

BioBasic





New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.